Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

NCT01426880 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT01426880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01426880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2011
Completion date
August 31, 2013
Enrollment
595 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female nos, her-2 positive breast cancer, inflammatory breast cancer, inflammatory breast cancer stage iv, invasive ductal breast cancer, mucinous breast cancer stage ii, tubular breast cancer stage ii, tubular breast cancer stage iii